Close Menu

NEW YORK (GenomeWeb) – Biocept reported after the close of the market on Wednesday that its first quarter revenues increased 27 percent year over year.

For the three months ended March 31, the San Diego-based liquid biopsy firm saw $1.0 million in revenues compared to $806,943 a year ago. These included about $976,000 in commercial test revenues and $42,000 from development services testing. The firm posted $6,000 in other revenues.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.